NCT07785869

Brief Summary

The purpose of this study is to assess changes in the characteristics of scalp hair among healthy female participants with mild to moderate hair loss, classified as Ludwig Scale I-3 to II-2

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
190

participants targeted

Target at P75+ for not_applicable

Timeline
1mo left

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
2 countries

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Jan 2026Sep 2026

Study Start

First participant enrolled

January 26, 2026

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 19, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 25, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 25, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 25, 2026

Last Updated

August 25, 2026

Status Verified

August 1, 2026

Enrollment Period

8 months

First QC Date

August 19, 2026

Last Update Submit

August 21, 2026

Conditions

Hair Characteristics

Keywords

Hair CharacteristicsHair ThicknessTopical SerumHair CareCosmetic Product

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in global scalp hair thickness/volume

    Clinical grading of the thickness of the global scalp hair using a 0-9 scoring scale

    Baseline, Day 180

Secondary Outcomes (5)

  • Change from baseline in global scalp hair thickness/volume

    Baseline, Day 90

  • Participant Perception

    Baseline, Day 90, Day 180

  • Comb test

    Baseline, Day 90, Day 180

  • Subgroup analysis: Change from baseline in target area hair thickness

    Baseline, Day 90, Day 180

  • Adverse Events

    Through study completion

Study Arms (3)

Re:You Hair Revival Serum 1

EXPERIMENTAL
Other: Re:You Hair Revival Serum 1

Re:You Hair Revival Serum 2

EXPERIMENTAL
Other: Re:You Hair Revival Serum 2

Topical Minoxidil 2% solution

ACTIVE COMPARATOR
Drug: Topical Minoxidil 2%

Interventions

Re:You Hair Revival Serum 1OTHER

Participants apply 1 mL (equivalent to two dropperfuls) of Re:You Hair Revival Serum 1 once daily to the scalp for 6 months.

Also known as: Product A, ReYou Sample 1, Product 1
Re:You Hair Revival Serum 1
Re:You Hair Revival Serum 2OTHER

Participants apply 1 mL (equivalent to two dropperfuls) of Re:You Hair Revival Serum 2 once daily to the scalp for 6 months.

Also known as: Product B, ReYou Sample 2, Product 2
Re:You Hair Revival Serum 2
Topical Minoxidil 2%DRUG

Participants apply 2 mL (equivalent to two dropperfuls) of topical minoxidil 2% solution once daily to the scalp for 6 months.

Also known as: OTC Product, Control, ReYou Sample 3, Product 3
Topical Minoxidil 2% solution

Eligibility Criteria

Age35 Years - 70 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsHealthy women 35 to 70 years of age
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant is female between 35 and 70 years of age;
  • Participant has mild to moderate hair loss, classified as Ludwig Scale I-3 to II-2;
  • Participant agrees not to use any hair products other than those required by the protocol (tonic, lacquer, gel, foam, etc.) until the end of the study;
  • Participant agrees not to change their shampoo, conditioner, or shampooing frequency and maintain a consistent hairstyle for the duration of the study;
  • Participant is willing to use only their regular, neutral mascara on their eyelashes and stop use of any other products on them for the duration of the study;
  • Participant is willing to not substantially change their current diet, medications, multivitamins or supplement, or exercise routines for the duration of the study;
  • Participant is in generally good health;
  • Participant understands and has signed an Informed Consent Form in conformance with 21 CFR Part 50: "Protection of Human Participants."

You may not qualify if:

  • Participant is pregnant, nursing, planning a pregnancy, or not using adequate birth control;
  • Participant wears a weave, extensions or dreadlocks or any other hairstyles that would interfere with the comb test;
  • Participant exhibits irritation, tattoos, sunburn, rashes, scratches, burn marks, scarring, etc. on the test site, which might interfere with evaluations of test results;
  • Participant is participating in another clinical study;
  • Participant has used Minoxidil, Finasteride or any topical and oral supplements or other therapies (such as light therapy) known to prevent or promote hair growth within the past 3 months;
  • Participant has been taking a stable dose of thyroid medication for a period of less than 4 months;
  • Participant has been taking a stable dose of GLP-1 (to manage diabetes or weight loss);
  • Participant has been taking a stable dose of hormonal medication (testosterone/ estrogen/progesterone) for a period of less than 6 months;
  • Participant has used any devices, prescriptions or OTC drugs that are known to affect the hair growth cycle within the past 6 months;
  • Participant uses medications known to affect the hair growth cycle within the last months such as cyproterone acetate, aldactone/spironolactone, finasteride, or other 5-alpha-reductase inhibitors;
  • Participant has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within one month prior to initiation of the study;
  • Participant has a history of acute or chronic dermatologic, medical, and/or physical conditions which would, in the opinion of the Principal Investigator, could influence the outcome of the study;
  • Participant is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study;
  • Participant has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs;
  • Participant is currently undergoing treatment for active cancer of any kind;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Eurofins | CRL, Cosmetics LLC

Piscataway, New Jersey, 08854, United States

Location

Eurofins Virginia Site

Forest, Virginia, 24551, United States

Location

Eurofins Consumer Product Testing (Guangzhou) Co., Ltd.

Guangzhou, Guangdong, 510289, China

Location

Related Publications (1)

  • Qu Z, Li Y, Cho SE, Doğan L, Yao Q, Tang L, Zhao G, Zhao EM, Li A, Omori S, Wong F, Zhang DKY. AI-enabled discovery of small molecules targeting complementary pathways for hair follicle rejuvenation. bioRxiv. June 12, 2026. doi: 10.64898/2026.06.09.728282.

    BACKGROUND

MeSH Terms

Interventions

Nonprescription Drugs

Intervention Hierarchy (Ancestors)

Pharmaceutical Preparations

Study Officials

  • Sarah Zeng

    Eurofins Consumer Product Testing (Guangzhou) Co., Ltd.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2026

First Posted

August 25, 2026

Study Start

January 26, 2026

Primary Completion (Estimated)

September 25, 2026

Study Completion (Estimated)

September 25, 2026

Last Updated

August 25, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will share

Locations

US(2)CN(1)